

## SYNTHESIS AND BIOLOGICAL ACTION OF 3-DEOXY-VITAMIN D<sub>3</sub> AND 3-DEOXY-25-HYDROXYVITAMIN D<sub>3</sub>

S. EDELSTEIN, M. SHEVES<sup>†</sup>, Y. MAZUR<sup>†</sup>, A. BAR\* and S. HURWITZ\*

*Biochemistry Department, The Weizmann Institute of Science, <sup>†</sup>Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot and \*Institute of Animal Science, Agricultural Research Organization, Bet-Dagan, Israel*

Received 31 October 1978

### 1. Introduction

1,25(OH)<sub>2</sub>D<sub>3</sub> is considered to be the active metabolite of vitamin D, particularly in the intestine. This compound is produced in vivo from vitamin D by C-25 hydroxylation in the liver, followed by C-1 hydroxylation in the kidney. When 1,25(OH)<sub>2</sub>D<sub>3</sub> interacts with intestinal cells, a specific CaBP is formed.

The characteristic functional groups of 1,25(OH)<sub>2</sub>D<sub>3</sub> are the 1 $\alpha$ , 3 $\beta$  and 25-hydroxy groups. Of these, only the 3 $\beta$ -hydroxyl is present in the parent vitamin molecule. Therefore, the 2-step transformation of the active form raises the question of the significance of this hydroxy group for the intermediary metabolism and the subsequent biological activity of the vitamin. Previous studies have shown however, that 3-deoxy analogues of 1,25(OH)<sub>2</sub>D<sub>3</sub> are only slightly less potent biologically than the natural metabolite [1–3].

This paper reports the chemical synthesis of 3-deoxy-D<sub>3</sub> and 3-deoxy-25(OH)D<sub>3</sub> and their biological activity in chicks. The latter was evaluated by monitoring growth, plasma calcium, bone ash, duodenal CaBP and the renal 25(OH)D<sub>3</sub>-1-hydroxylase.

### 2. Experimental

#### 2.1. Measurements of biological activity

Day-old White Leghorn males kept in a windowless room were fed for 28 days a semi-purified vitamin D-deficient diet containing 1.2% calcium and 0.7% phosphorus [4]. At the age of 21 days, the chicks were divided into 5 groups. Birds of each group were injected subcutaneously either with daily doses of 0.25  $\mu$ g D<sub>3</sub>, 0.25 or 100  $\mu$ g 3-deoxy-D<sub>3</sub>, or 0.25 or 100  $\mu$ g 3-deoxy-25(OH)D<sub>3</sub>. The sterols were dissolved in propylene glycol.

At the age of 28 days, heparinized blood samples were obtained from 6 birds of each group before they were killed by dislocation of the neck. Plasma calcium concentration was determined by an EGTA titration using an automatic titrator (Precision Systems, USA). The duodenal mucosa was homogenized [5] and assayed for CaBP using a radioimmunoassay with a sensitivity of 30 pg [6].

Bones were cleaned of adhering tissues, dried and ashed [7].


#### 2.2. Synthesis of 3-deoxy-25(OH)D<sub>3</sub> and 3-deoxy-D<sub>3</sub> (scheme 1)

##### 2.2.1. 3-Tosyl-25(OH)D<sub>3</sub> (2b)

150 mg of 25(OH)D<sub>3</sub> (1b) were dissolved in 4 ml dry pyridine. The solution was treated with 115 mg tosyl chloride and left at room temperature (25°C) overnight. The reaction mixture was then extracted

*Abbreviations:* D<sub>3</sub>, vitamin D<sub>3</sub>; 25(OH)D<sub>3</sub>, 25-hydroxyvitamin D<sub>3</sub>; 1(OH)D<sub>3</sub>, 1-hydroxyvitamin D<sub>3</sub>; 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1,25-dihydroxyvitamin D<sub>3</sub>; CaBP, calcium-binding protein; TLC, thin-layer chromatography

Scheme 1  
Synthetic steps for the preparation of 3-deoxy-D<sub>3</sub>  
and 3-deoxy-25(OH)D<sub>3</sub>



with diethyl ether, washed with cold 5% aq. HCl and with water, and dried over MgSO<sub>4</sub>. The diethyl ether was evaporated and the residue was chromatographed on a preparative silica-gel TLC plate with diethyl ether. The resulting compound (2b) (100 mg) (ultraviolet  $\lambda_{\max}$  264 nm, 232 nm;  $\epsilon$ , 17 500, 14 000 l. mol<sup>-1</sup> . cm<sup>-1</sup>) showed by <sup>1</sup>H NMR spectroscopy signals at  $\delta$  0.55, 1.13, 4.66, 4.76, 4.99, 5.87, 6.02, 7.26 and 7.71 ppm, *m/e* (*M*<sup>+</sup>) 554.

#### 2.2.2. 3-Deoxy-D<sub>3</sub> (3a)

D<sub>3</sub>-tosylate (2a) [8] 100 mg were dissolved in 6 ml dry tetrahydrofuran and chilled to 0°C. The solution was treated with 0.2 ml 2 M lithium triisobutylborohydride solution and was left for 30 min at 0°C and 6 h at room temperature (25°C). Excess hydride was decomposed with water. The organoborane was oxidized with 5 ml 3 N NaOH and 5 ml 30% H<sub>2</sub>O<sub>2</sub>. The mixture was then extracted with pentane, washed with water and dried over MgSO<sub>4</sub>. The dry residue was chromatographed on a preparative silica-gel TLC plate with hexane. The resulting compound, 3-deoxy-D<sub>3</sub> (3a) (20 mg) ( $\lambda_{\max}$ , 264 nm;  $\epsilon$ , 17 500 l. mol<sup>-1</sup> cm<sup>-1</sup>), showed by <sup>1</sup>H NMR spectroscopy signals at  $\delta$  0.55, 4.66, 4.92, 5.92 and 6.02 ppm, *m/e* (*M*<sup>+</sup>) 366.3464 (calc. 366.3453).

#### 2.2.3. 3-Deoxy-25(OH)D<sub>3</sub> (3b)

3-Tosyl-25(OH)D<sub>3</sub> (2b), 100 mg, were treated as above but the resulting reaction mixture was chromatographed on a preparative silica-gel TLC plate with hexane/diethyl ether (2:1, v/v). The resulting compound 3-deoxy-25(OH)D<sub>3</sub> (3b) (15 mg) ( $\lambda_{\max}$  264 nm;  $\epsilon$ , 17 500 l. mol<sup>-1</sup> cm<sup>-1</sup>) showed

by <sup>1</sup>H NMR spectroscopy signals at  $\delta$  0.55, 1.13, 4.66, 4.92, 5.92 and 9.02 ppm, *m/e* (*M*<sup>+</sup>) 384.3375 (calc. 384.3392).

#### 2.3. Renal 25(OH)D<sub>3</sub>-1-hydroxylase

Three vitamin D-deficient chicks were killed by decapitation, their kidneys were removed, washed with cold saline, pooled and homogenised. The homogenate was assayed for 1-hydroxylase activity by 10 min incubation with [26, 27-<sup>3</sup>H]25(OH)D<sub>3</sub> or [26, 27-<sup>3</sup>H]3-deoxy-25(OH)D<sub>3</sub> as substrates [9]. The concentration of either substrate was 15 ng/1.5 ml incubation mixture. The metabolites produced were chromatographed on Sephadex LH-20 columns. The columns (1 × 65 cm) were equilibrated and developed with chloroform : petroleum ether 40°–60° : methanol (75:23:2, v/v/v) [10].

#### 2.4. Radioactive materials and measurements

[26, 27-<sup>3</sup>H]25(OH)D<sub>3</sub> (spec. radioact. 9.0 Ci/mmol) was obtained from the Radiochemical Centre (Amersham, Bucks).

[26, 27-<sup>3</sup>H]3-deoxy-25(OH)D<sub>3</sub> was prepared in our laboratories from [26, 27-<sup>3</sup>H]25(OH)D<sub>3</sub> as above.

All radioactivity measurements were carried out in a Packard Tri-Carb automatic liquid-scintillation spectrometer no. 3390. Lipid samples were counted for radioactivity in a solution of 100 mg 1,4-bis-(5-phenyloxazol-2-yl) benzene and 4 mg 2,5-diphenyloxazole/l. toluene. Quenching was corrected for by using the automatic external standardization and correlation curve for <sup>3</sup>H.

### 3. Results

Results shown in table 1 indicate that final body weight and % bone ash were significantly (*P* < 0.05) higher in the D<sub>3</sub> and the high 3-deoxy-25(OH)D<sub>3</sub>-treated chicks than in the other 3 groups which did not differ significantly (*P* > 0.05) from each other. Plasma calcium concentration was normal only in the D<sub>3</sub> and the high 3-deoxy-25(OH)D<sub>3</sub>-treated birds. Hypocalcemia was observed in all other groups, although in the birds which were treated with high doses of 3-deoxy-D<sub>3</sub> the severity of the hypocalcemia was reduced.

Duodenal CaBP was high in the D<sub>3</sub>-treated chicks,

Table 1  
Body weight, plasma calcium, bone ash and duodenal CaBP of chicks treated with the various vitamin D derivatives

Vitamin D derivative	Dose ( $\mu\text{g/day}$ )	Final body weight (g)	Plasma calcium (mg/dl)	Bone ash (%)	Duodenal CaBP (mg/g)
D <sub>3</sub>	0.25	222 $\pm$ 4 <sup>a,f</sup>	10.6 $\pm$ 0.2 <sup>a</sup>	37.0 $\pm$ 0.7 <sup>a</sup>	1405 $\pm$ 97 <sup>a</sup>
3-Deoxy-D <sub>3</sub>	0.25	174 $\pm$ 13 <sup>b</sup>	6.3 $\pm$ 0.1 <sup>b</sup>	28.3 $\pm$ 0.9 <sup>b</sup>	11 $\pm$ 2 <sup>b</sup>
3-Deoxy-D <sub>3</sub>	100	176 $\pm$ 9 <sup>b</sup>	8.4 $\pm$ 0.7 <sup>c</sup>	29.2 $\pm$ 0.3 <sup>b</sup>	133 $\pm$ 17 <sup>c</sup>
3-Deoxy-25(OH)D <sub>3</sub>	0.25	178 $\pm$ 15 <sup>b</sup>	5.9 $\pm$ 0.2 <sup>b</sup>	27.6 $\pm$ 0.9 <sup>b</sup>	45 $\pm$ 3 <sup>d</sup>
3-Deoxy-25(OH)D <sub>3</sub>	100	222 $\pm$ 15 <sup>a</sup>	10.7 $\pm$ 0.4 <sup>a</sup>	38.1 $\pm$ 0.5 <sup>a</sup>	924 $\pm$ 170 <sup>e</sup>

<sup>a-e</sup> Means designated by different letters differ significantly ( $P < 0.01$ )

<sup>f</sup> Mean  $\pm$  SEM, obtained from 6 birds

slightly lower in the high 3-deoxy-25(OH)D<sub>3</sub>-treated chicks, and very low in the rest. The levels measured in the low 3-deoxy-D<sub>3</sub>-treated chicks were close to the detection limit. Slightly higher levels were measured in the low 3-deoxy-25(OH)D<sub>3</sub>-treated chicks, and still higher levels for high 3-deoxy-D<sub>3</sub>-treated chicks. Since the most important functional group of 1,25(OH)<sub>2</sub>D<sub>3</sub> is the hydroxyl at C-1, the observed biological effectiveness of 3-deoxy-25(OH)D<sub>3</sub>, which was found to be lower than that of D<sub>3</sub>, suggested that 1-hydroxylation of 3-deoxy-D<sub>3</sub> might be impaired. In order to test this possibility, kidney homogenates obtained from vitamin D-deficient chicks were incubated with either [26, 27-<sup>3</sup>H]25(OH)D<sub>3</sub> or [26, 27-<sup>3</sup>H]3-deoxy-25(OH)D<sub>3</sub>. Results given in fig.1 show that the conversion of [26, 27-<sup>3</sup>H]3-deoxy-25(OH)D<sub>3</sub> into its corresponding 1-hydroxylated derivative was impaired. The efficiency of the conversions of [26, 27-<sup>3</sup>H]3-deoxy-25(OH)D<sub>3</sub> and of [26, 27-<sup>3</sup>H]25(OH)D<sub>3</sub> to their 1-hydroxylated derivatives were estimated at 3.8% and 14.3%, respectively.

#### 4. Discussion

This report details the chemical synthesis of 3-deoxy-D<sub>3</sub> and 3-deoxy-25(OH)D<sub>3</sub>, which lack the 3 $\beta$ -hydroxyl of the natural vitamin. The synthesis was achieved in 2 steps from D<sub>3</sub> or from 25(OH)D<sub>3</sub>, respectively. Of the several criteria used here to evaluate the biological activity of these analogues of vitamin D, intestinal CaBP appeared to be most sensitive, in agreement with [11,12]. Furthermore,




Fig.1. Sephadex LH-20 chromatography of lipid extracts from kidney homogenates which were incubated with [26, 27-<sup>3</sup>H]25(OH)D<sub>3</sub> (A) and [26, 27-<sup>3</sup>H]3-deoxy-25(OH)D<sub>3</sub> (B). Curves: (A) peaks 1 and 2 are 25(OH)D<sub>3</sub> and 1,25(OH)<sub>2</sub>D<sub>3</sub>, respectively; (B) peaks 1 and 2 are 3-deoxy-25(OH)D<sub>3</sub> and 3-deoxy-1,25(OH)<sub>2</sub>D<sub>3</sub>, respectively.

the present radioimmunoassay with its high sensitivity, made possible the distinction between vitamin D analogues which possess a low biological activity.

A 0.25  $\mu\text{g}$   $\text{D}_3$ /day dose was sufficient to promote normal weight gain, bone ash, plasma calcium and duodenal CaBP. The two 3-deoxy-analogues given at the same doses were found to be inactive, although a slight response in terms of duodenal CaBP was noted with 3-deoxy-25(OH) $\text{D}_3$ . With doses as high as 100  $\mu\text{g}$ /day, 3-deoxy-25(OH) $\text{D}_3$  produced a response similar to the lower dose of  $\text{D}_3$ . The 3-deoxy- $\text{D}_3$ , on the other hand, produced only marginal responses. Thus, 3-deoxy-25(OH) $\text{D}_3$  is more potent biologically than 3-deoxy- $\text{D}_3$ , and the 3 $\beta$ -hydroxyl is required for the 25-hydroxylation step of  $\text{D}_3$ .

The low biological activity of 3-deoxy-25(OH) $\text{D}_3$  relative to  $\text{D}_3$  itself, suggested that the 3 $\beta$ -hydroxyl was required for the 1-hydroxylation step in the kidney. This has been demonstrated also by the poor in vitro conversion of this analogue to its 1-hydroxy-derivative by kidney homogenates. However, the 3-deoxy-analogues which had already been hydroxylated at C-1, were shown [3] only slightly inferior to 1,25(OH) $_2\text{D}_3$ . Therefore, the 3 $\beta$ -hydroxy group is more important for the intermediary metabolism of the vitamin than for its action on the target organ.

### Acknowledgements

The authors thank Professor R. H. Wasserman of Cornell University, Ithaca, New York, for the generous supply of the specific antiserum. The technical assistance of Mrs M. Cotter and R. Yemini is gratefully acknowledged.

### References

- [1] Lam, H. Y., Onisko, B. L., Schnoes, H. K. and DeLuca, H. F. (1974) *Biochem. Biophys. Res. Commun.* 59, 845–849.
- [2] Okamura, W. H., Mitra, M. N., Wing, R. M. and Norman, A. W. (1974) *Biochem. Biophys. Res. Commun.* 60, 179–185.
- [3] Okamura, W. H., Mitra, M. N., Procsal, D. A. and Norman, A. W. (1975) *Biochem. Biophys. Res. Commun.* 65, 24–30.
- [4] Bar, A., Dubrov, D., Eisner, U. and Hurwitz, S. (1978) *J. Nutrit.* 108, 1501–1506.
- [5] Wasserman, R. H. and Taylor, A. N. (1966) *Science* 152, 791–793.
- [6] Bar, A. and Hurwitz, S. (1979) in preparation.
- [7] Bar, A., Hurwitz, S. and Edelstein, S. (1975) *Biochim. Biophys. Acta* 411, 106–112.
- [8] Sheves, M. and Mazur, Y. (1975) *J. Am. Chem. Soc.* 97, 6249–6251.
- [9] Fraser, D. R. and Kodicek, E. (1970) *Nature* 228, 764–766.
- [10] Holick, M. F., Kleiner-Bossaller, A., Schnoes, H. K., Kastern, P. M., Boyle, I. T. and DeLuca, H. F. (1975) *J. Biol. Chem.* 248, 6691–6696.
- [11] Bar, A. and Wasserman, R. H. (1973) *Biochem. Biophys. Res. Commun.* 54, 191–196.
- [12] Bronner, F. and Freund, T. (1975) *Am. J. Physiol.* 229, 684–694.